Renal fibrosis is the common end point of virtually all progressive kidney diseases and a detailed understanding of the underlying mechanisms is required for the development of effective therapeutic strategies. In this Review, Boor and colleagues discuss the most recent advances in renal, or more specifically, tubulointerstitial fibrosis. Consideration is given to novel mechanisms as well as potential treatment targets based on different cell types.
- Peter Boor
- Tammo Ostendorf
- Jürgen Floege
